Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis

Abstract Objective To review outcomes in randomised controlled trials comparing hydralazine against other antihypertensives for severe hypertension in pregnancy. Study design Meta-analysis of randomised controlled trials (published between 1966 and September 2002) of short acting antihypertensives for severe hypertension in pregnancy. Independent data abstraction by two reviewers. Data were entered into RevMan software for analysis (fixed effects model, relative risk and 95% confidence interval); in a secondary analysis, risk difference was also calculated. Results Of 21 trials (893 women), eight compared hydralazine with nifedipine and five with labetalol. Hydralazine was associated with a trend towards less persistent severe hypertension than labetalol (relative risk 0.29 (95% confidence interval 0.08 to 1.04); two trials), but more severe hypertension than nifedipine or isradipine (1.41 (0.95 to 2.09); four trials); there was significant heterogeneity in outcome between trials and differences in methodological quality. Hydralazine was associated with more maternal hypotension (3.29 (1.50 to 7.23); 13 trials); more caesarean sections (1.30 (1.08 to 1.59); 14 trials); more placental abruption (4.17 (1.19 to 14.28); five trials); more maternal oliguria (4.00 (1.22 to 12.50); three trials); more adverse effects on fetal heart rate (2.04 (1.32 to 3.16); 12 trials); and more low Apgar scores at one minute (2.70 (1.27 to 5.88); three trials). For all but Apgar scores, analysis by risk difference showed heterogeneity between trials. Hydralazine was associated with more maternal side effects (1.50 (1.16 to 1.94); 12 trials) and with less neonatal bradycardia than labetalol (risk difference -0.24 (-0.42 to -0.06); three trials). Conclusions The results are not robust enough to guide clinical practice, but they do not support use of hydralazine as first line for treatment of severe hypertension in pregnancy. Adequately powered clinical trials are needed, with a comparison of labetalol and nifedipine showing the most promise.

[1]  D. Henderson-smart,et al.  Drugs for treatment of very high blood pressure during pregnancy. , 2013, The Cochrane database of systematic reviews.

[2]  D. Altman,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[3]  B. S. Aali,et al.  Nifedipine or hydralazine as a first‐line agent to control hypertension in severe preeclampsia , 2002, Acta obstetricia et gynecologica Scandinavica.

[4]  M. Schulz,et al.  Auswirkungen von Urapidil in der antihypertensiven Therapie bei Präeklampsie auf die Neugeborenen , 2001 .

[5]  J. Higgins,et al.  The detection, investigation and management of hypertension in pregnancy: executive summary , 2000, The Australian & New Zealand journal of obstetrics & gynaecology.

[6]  R. Newman,et al.  A randomized, double-blind trial of oral nifedipine and intravenous labetalol in hypertensive emergencies of pregnancy. , 1999, American journal of obstetrics and gynecology.

[7]  H. V. van Geijn,et al.  Ketanserin versus dihydralazine in the management of severe early-onset preeclampsia: maternal outcome. , 1999, American journal of obstetrics and gynecology.

[8]  J A Staessen,et al.  Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension , 1998, Journal of hypertension.

[9]  H. Geijn,et al.  The haemodynamic effects of ketanserin versus dihydralazine in severe early‐onset hypertension in pregnancy , 1998, British journal of obstetrics and gynaecology.

[10]  J. Cutler.  Calcium-channel blockers for hypertension--uncertainty continues. , 1998, The New England journal of medicine.

[11]  H. Odendaal,et al.  Dihydralazine or ketanserin for severe hypertension in pregnancy? Preliminary results. , 1997, European journal of obstetrics, gynecology, and reproductive biology.

[12]  E. Burgess,et al.  Report of the Canadian Hypertension Society Consensus Conference: 3. Pharmacologic treatment of hypertensive disorders in pregnancy. , 1997, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[13]  Jan A Staessen,et al.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension , 1997, The Lancet.

[14]  M. Brown,et al.  Withdrawal of nifedipine capsules: jeopardising the treatment of acute severe hypertension in pregnancy? , 1997 .

[15]  S. Office.  Report on Confidential Enquiries into Maternal Deaths in the United Kingdom 1991-1993 , 1996 .

[16]  B. Sibai,et al.  Management of severe preeclampsia. , 1996, Current opinion in obstetrics & gynecology.

[17]  R. Jegasothy,et al.  Sublingual Nifedipine Compared with Intravenous Hydrallazine in the Acute Treatment of Severe Hypertension in Pregnancy: Potential for Use in Rural Practice , 1996, The journal of obstetrics and gynaecology research.

[18]  R. Guillet,et al.  Use of glucagon to treat neonatal low-output congestive heart failure after maternal labetalol therapy. , 1995, The Journal of pediatrics.

[19]  E. Y. Kwawukume,et al.  Oral nifedipine therapy in the management of severe preeclampsia , 1995, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[20]  H. Odendaal,et al.  Ketanserin and hydralazine in hypertension in pregnancy--a randomised double-blind trial. , 1995, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[21]  J. Moodley,et al.  Intravenous isradipine in the management of severe hypertension in pregnant and nonpregnant patients. A pilot study. , 1994, American journal of hypertension.

[22]  E. Shalev,et al.  The combination of magnesium sulphate and nifedipine: a cause of neuromuscular blockade , 1994, British journal of obstetrics and gynaecology.

[23]  L. Impey.  Severe hypotension and fetal distress following sublingual administration of nifedipine to a patient with severe pregnancy induced hypertension at 33 weeks , 1993, British journal of obstetrics and gynaecology.

[24]  C. Rout,et al.  Malignant ventricular arrhythmias in eclampsia: a comparison of labetalol with dihydralazine. , 1993, American journal of obstetrics and gynecology.

[25]  J. Moodley,et al.  A comparative study of the use of epoprostenol and dihydralazine in severe hypertension in pregnancy. , 1993, British journal of obstetrics and gynaecology.

[26]  W. Rj,et al.  [Management of severe pre-eclampsia/eclampsia. Comparison between nifedipine and hydralazine as antihypertensive agents]. , 1993, Ginecologia y obstetricia de Mexico.

[27]  A. Stewart,et al.  Antihypertensive Drug Effects on Placental Flow Velocity Waveforms in Pregnant Women with Severe Hypertension , 1992, The Australian & New Zealand journal of obstetrics & gynaecology.

[28]  K. S. Olsen,et al.  Fetal death following labetalol administration in pre‐eclampsia , 1992, Acta obstetricia et gynecologica Scandinavica.

[29]  A. Harper,et al.  Maternal and fetal haemodynamics in hypertensive pregnancies during maternal treatment with intravenous hydralazine or labetalol , 1991, British journal of obstetrics and gynaecology.

[30]  S. Lurie,et al.  Nifedipine in the Treatment of Severe Preeclampsia , 1991, Obstetrics and gynecology.

[31]  P. Becker,et al.  Nifedipine in acute hypertensive emergencies in pregnancy. , 1989, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[32]  M. Cardwell,et al.  Neuromuscular blockade with magnesium sulfate and nifedipine , 1989 .

[33]  L. M. Mayorga,et al.  Magnesium Plus Nifedipine: Potentiation of Hypotensive Effect in Preeclampsia? , 1988, American journal of obstetrics and gynecology.

[34]  E. Amon,et al.  A comparative trial of labetalol and hydralazine in the acute management of severe hypertension complicating pregnancy , 1987, Obstetrics and gynecology.

[35]  R. H. Philpott,et al.  Comparison of labetalol and dihydralazine in hypertensive emergencies of pregnancy. , 1987, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[36]  J. Moodley,et al.  The effect of low-dose dihydrallazine on the fetus in the emergency treatment of hypertension in pregnancy. , 1982, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[37]  R. H. Philpott,et al.  Effect of dihydralazine on the fetus in the treatment of maternal hypertension. , 1980, Obstetrics and gynecology.

[38]  D. Henderson-smart,et al.  Drugs for rapid treatment of very high blood pressure during pregnancy. , 2000, The Cochrane database of systematic reviews.

[39]  Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. , 2000, American journal of obstetrics and gynecology.

[40]  R. North,et al.  Withdrawal of nifedipine capsules: jeopardizing the treatment of acute severe hypertension in pregnancy? Australasian Society for the Study of Hypertension in Pregnancy. , 1997, The Medical journal of Australia.

[41]  R. Pattinson,et al.  A Randomized Controlled Pilot Study Comparing Urapidil to Dihydralazine in the Management of Severe Hypertension in Pregnancy , 1997 .

[42]  J. Moodley,et al.  A Comparative Study of Intravenous Isradipine and Dihydralazine in the Treatment of Severe Hypertension of Pregnancy in Black Patients , 1997 .

[43]  E. O’Brien,et al.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. , 1997, Lancet.

[44]  Bryan M. Hibbard,et al.  Report on confidential enquiries into maternal deaths in the United Kingdom 1991-1993 , 1996 .

[45]  J. Moodley,et al.  Intravenous isradipine in the management of severe hypertension of pregnancy in black patients: a pilot study. , 1994, Blood pressure. Supplement.

[46]  E. Barros,et al.  Randomized, Controlled Trial of Hydralazine Versos Nifedipine in Preeclamptic Women with Acute Hypertension , 1992 .

[47]  D. Wlody,et al.  Hypertension in pregnancy. , 1992, The New England journal of medicine.

[48]  J. Ashley,et al.  Report on Confidential Enquiries into Maternal Deaths in England and Wales 1982-1984. , 1989, Reports on health and social subjects.

[49]  J. Dommisse,et al.  Intravenous labetalol and intravenous dihydralazine in severe hypertension in pregnancy. , 1982, Clinical and experimental hypertension. Part B, Hypertension in pregnancy.

[50]  G. Bastert,et al.  Treatment of hypertension in patients with pre-eclampsia: a prospective parallel-group study comparing dihydralazine with urapidil. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.